• Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues


Patheon N.V Expands Greenville, North Carolina, Manufacturing Campus

Patheon N.V, a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, completed an expansion project at its manufacturing site in Greenville, North Carolina.

According to company officials, “another exciting development in Greenville is the installation of a state of the art continuous manufacturing suite.”

The company’s Greenville manufacturing site is a large multi-purpose pharmaceutical manufacturing and packaging campus. The facility provides both solid dose form manufacturing/packaging and sterile dose manufacturing, filling and lyophilization of both biopharmaceuticals and small molecules.

The company invested approximately $26 million to update one of its sterile Pharmaceutical Development Services suites and to build a state-of-the-art, fully integrated sterile PDS suite which are compliant with regulatory authorities. The PDS Suites 1 and 2 provide 7,000-square-feet in GMP steriles manufacturing space.

The newly built PDS suite will manufacture sterile liquid and lyophilized drug products. It features freeze dryers and a fully integrated filling line fitted with a Restricted Access Barrier System (RABS) for sterile drug products.

Patheon has made the investment in disposable manufacturing in this suite eliminating the need for cleaning verification for liquid filling, reducing setup time/product losses and enhancing sterility assurance, officials said. This suite is highly sophisticated, fully integrated and designed for products in clinical development with the ability to scale up to much larger batch sizes via Patheon’s network of commercial scale capabilities either co-existing within the Greenville facility, or in Europe.

“As the industry continues to innovate, customers will require even more advanced solutions, integrating development and commercial service, to meet their business needs,” said Franco Negron, President of Patheon’s drug product and pharmaceutical development services for North America.

“The increasing focus on pharma to reduce costs will lead forward-thinking companies to capitalize on their core competencies, focusing on what they do best, while strategically partnering with companies such as Patheon to deliver the expertise, customized solutions and technical capabilities to support the production of their small and large molecule products,” he added.

Exclusive Research